{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:18:22Z","timestamp":1761488302141},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.beha.2009.04.002","type":"journal-article","created":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T08:16:41Z","timestamp":1250756201000},"page":"181-190","source":"Crossref","is-referenced-by-count":25,"title":["The impact of gene profiling in chronic myeloid leukaemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Agnes S.M.","family":"Yong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2009.04.002_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000140633","article-title":"BCR-ABL in chronic myelogenous leukemia - how does it work?","volume":"119","author":"Goldman","year":"2008","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.beha.2009.04.002_bib3","first-page":"2049","article-title":"BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia","volume":"60","author":"Deininger","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2009.04.002_bib4","first-page":"173","article-title":"BCR\/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia","volume":"2","author":"Salesse","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"Suppl.","key":"10.1016\/j.beha.2009.04.002_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ng1030","article-title":"Options available\u2013from start to finish\u2013for obtaining data from DNA microarrays II","volume":"32","author":"Holloway","year":"2002","journal-title":"Nat Genet"},{"issue":"Suppl.","key":"10.1016\/j.beha.2009.04.002_bib6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/ng1029","article-title":"Medical applications of microarray technologies: a regulatory science perspective","volume":"32","author":"Petricoin","year":"2002","journal-title":"Nat Genet"},{"issue":"Suppl.","key":"10.1016\/j.beha.2009.04.002_bib7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ng1033","article-title":"From patterns to pathways: gene expression data analysis comes of age","volume":"32","author":"Slonim","year":"2002","journal-title":"Nat Genet"},{"issue":"5439","key":"10.1016\/j.beha.2009.04.002_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.286.5439.531","article-title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","volume":"286","author":"Golub","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.beha.2009.04.002_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/73432","article-title":"Systematic variation in gene expression patterns in human cancer cell lines","volume":"24","author":"Ross","year":"2000","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.beha.2009.04.002_bib10","first-page":"535","article-title":"Critical role for cyclin D2 in BCR\/ABL-induced proliferation of hematopoietic cells","volume":"62","author":"Jena","year":"2002","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.beha.2009.04.002_bib11","first-page":"8005","article-title":"Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts","volume":"61","author":"Deininger","year":"2001","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.beha.2009.04.002_bib12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2009.04.002_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"issue":"5531","key":"10.1016\/j.beha.2009.04.002_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.beha.2009.04.002_bib15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0301-472X(03)00265-0","article-title":"Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate","volume":"31","author":"Tipping","year":"2003","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.beha.2009.04.002_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1634\/stemcells.21-3-315","article-title":"Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22\/SR","volume":"21","author":"Ohmine","year":"2003","journal-title":"Stem Cells"},{"issue":"8","key":"10.1016\/j.beha.2009.04.002_bib17","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.04.002_bib18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2009.04.002_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/leu.2008.47","article-title":"Experimental non-ATP-competitive therapies for chronic myelogenous leukemia","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2009.04.002_bib20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy","volume":"22","author":"McCubrey","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2009.04.002_bib21","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/sj.leu.2404310","article-title":"Gene expression signatures associated with the resistance to imatinib","volume":"20","author":"Chung","year":"2006","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.beha.2009.04.002_bib22","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/sj.onc.1206620","article-title":"Chronic myelogenous leukemia molecular signature","volume":"22","author":"Nowicki","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.beha.2009.04.002_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cyto.a.20055","article-title":"Getting the right cells to the array: gene expression microarray analysis of cell mixtures and sorted cells","volume":"59A","author":"Szaniszlo","year":"2004","journal-title":"Cytometry"},{"issue":"34","key":"10.1016\/j.beha.2009.04.002_bib24","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1038\/sj.onc.1208596","article-title":"Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia","volume":"24","author":"Kronenwett","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.beha.2009.04.002_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.leu.2404549","article-title":"Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase","volume":"21","author":"Diaz-Blanco","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2009.04.002_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2009.04.002_bib27","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/blood-2007-09-114975","article-title":"Transcriptional repression of c-Myb and GATA-2 is involved in the biological effects of C\/EBP{alpha} in p210 BCR\/ABL-expressing cells","volume":"112","author":"Soliera","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib28","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.0711824105","article-title":"Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.beha.2009.04.002_bib29","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"issue":"57","key":"10.1016\/j.beha.2009.04.002_bib30","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1038\/sj.onc.1205029","article-title":"Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells","volume":"20","author":"Ohmine","year":"2001","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2009.04.002_bib32","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1182\/blood.V99.5.1766","article-title":"Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism","volume":"99","author":"Schultheis","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.04.002_bib33","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"10.1016\/j.beha.2009.04.002_bib34","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.beha.2009.04.002_bib35","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-05-2578","article-title":"Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy","volume":"12","author":"Griffioen","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2009.04.002_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2009.04.002_bib37","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","article-title":"Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells","volume":"88","author":"Molldrem","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.04.002_bib38","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.beha.2009.04.002_bib39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","article-title":"Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells","volume":"111","author":"Molldrem","year":"2003","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.beha.2009.04.002_bib40","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood-2007-02-071738","article-title":"High PR3 or ELA2 expression by CD34+ cells in advanced phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide driven graft-versus-leukemia effects","volume":"110","author":"Yong","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2009.04.002_bib41","doi-asserted-by":"crossref","DOI":"10.4161\/cc.5.24.3573","article-title":"Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia","volume":"5","author":"Barnes","year":"2006","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.beha.2009.04.002_bib42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.04.002_bib43","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.04.002_bib44","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib45","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2009.04.002_bib46","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1634\/stemcells.2007-0250","article-title":"Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources","volume":"25","author":"Graham","year":"2007","journal-title":"Stem Cells"},{"issue":"7191","key":"10.1016\/j.beha.2009.04.002_bib47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2009.04.002_bib48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/10428190801947500","article-title":"Ikaros and acute leukemia","volume":"49","author":"Mullighan","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.beha.2009.04.002_bib49","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gad.1673908","article-title":"Failure of CDKN2A\/B (INK4A\/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL","volume":"22","author":"Mullighan","year":"2008","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.beha.2009.04.002_bib50","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2007-09-112631","article-title":"Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance","volume":"112","author":"Iacobucci","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2009.04.002_bib51","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa032520","article-title":"Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes","volume":"350","author":"Lossos","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2009.04.002_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling","volume":"1","author":"Yeoh","year":"2002","journal-title":"Cancer Cell"},{"issue":"9305","key":"10.1016\/j.beha.2009.04.002_bib53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(02)07678-X","article-title":"Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study","volume":"359","author":"Hofmann","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2009.04.002_bib54","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/10428190801896194","article-title":"Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia","volume":"49","author":"Schmidt","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib55","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.04.002_bib56","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.04.002_bib57","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1349-7006.2002.tb01328.x","article-title":"Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis","volume":"93","author":"Kaneta","year":"2002","journal-title":"Jpn J Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2009.04.002_bib58","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures","volume":"90","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"issue":"1 Pt 1","key":"10.1016\/j.beha.2009.04.002_bib59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-0784-3","article-title":"Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib","volume":"10","author":"McLean","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2009.04.002_bib60","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","article-title":"Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients","volume":"20","author":"Frank","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib61","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","article-title":"Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach","volume":"20","author":"Villuendas","year":"2006","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2009.04.002_bib62","doi-asserted-by":"crossref","first-page":"305a","DOI":"10.1182\/blood.V110.11.1007.1007","article-title":"A transcriptomal profile for predicting complete cytogenetic response (CCR) in chronic phase CML patients treated with imatinib","volume":"110","author":"McWeeney","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2009.04.002_bib63","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/sj.leu.2403615","article-title":"Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib","volume":"19","author":"Neumann","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2009.04.002_bib64","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.leukres.2006.11.015","article-title":"Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients","volume":"31","author":"Hagberg","year":"2007","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib65","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/leu.2008.30","article-title":"MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications","volume":"22","author":"Fabbri","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2009.04.002_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ccr.2007.07.027","article-title":"Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas","volume":"12","author":"Calin","year":"2007","journal-title":"Cancer Cell"},{"issue":"7043","key":"10.1016\/j.beha.2009.04.002_bib67","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature03677","article-title":"c-Myc-regulated microRNAs modulate E2F1 expression","volume":"435","author":"O'Donnell","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.beha.2009.04.002_bib68","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","author":"Venturini","year":"2007","journal-title":"Blood"},{"issue":"7043","key":"10.1016\/j.beha.2009.04.002_bib69","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2009.04.002_bib70","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.beha.2009.04.002_bib71","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ccr.2008.05.013","article-title":"Linking miRNA regulation to BCR-ABL expression: the next dimension","volume":"13","author":"Faber","year":"2008","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.beha.2009.04.002_bib73","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression","volume":"13","author":"Bueno","year":"2008","journal-title":"Cancer Cell"},{"issue":"7046","key":"10.1016\/j.beha.2009.04.002_bib74","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2009.04.002_bib75","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/stemcells.2006-0638","article-title":"Chronic myeloid leukemia blast crisis arises from progenitors","volume":"25","author":"Michor","year":"2007","journal-title":"Stem Cells"},{"issue":"10","key":"10.1016\/j.beha.2009.04.002_bib76","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T15:35:53Z","timestamp":1590075353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S1521692609000231"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.04.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}